Orexigen Eyes Earlier Resubmission Of Contrave NDA
This article was originally published in The Pink Sheet Daily
Executive Summary
The company is optimistic it can work out an agreement with FDA to re-file the obesity drug application before it has interim data from a cardiovascular outcomes trial in hand.
You may also be interested in...
Eric Colman, FDA’s Lead Obesity Drug Reviewer, Dies At Age 53
As a reviewer, team leader and deputy director in the Division of Metabolism and Endocrinology Products, Colman spearheaded the agency’s policy development on weight-management products.
If At First You Don’t Succeed, Try Dispute Resolution
More companies are turning to CDER’s formal appeals process when presented with a review division’s regulatory decision or advice. Even though few appeals are granted in full, many sponsors get valuable clarity on a path forward; some appeals, like that for Amarin’s Vascepa SPA, are turned away at the door.
Orexigen Defines A Way To Get The Contrave PDUFA Clock Ticking
The summary report of an interim analysis of the ongoing LIGHT clinical trial evaluating the cardiovascular safety of the obesity medicine can form the basis of a resubmission of the Contrave NDA, the company announced, shaving some time off the PDUFA clock.